Checkpoint Inhibitors: Attack on the Tumor…and Kidney
The use of checkpoint inhibitors (CPIs) has revolutionized the approach to therapy in patients with aggressive hematological and metastatic solid malignancies. These novel immunotherapies have increased overall survival for our patients with an improved overall side effect profile…